Identification of Myocardial Damage in Systemic Sclerosis: A Nuclear Cardiology Approach

You are here:

Author: Kenichi Nakajima, Shinro Matsuo, Minoru Hasegawa, Seigo Kinuya, and Kazuhiko Takehara
Date Published: August-2010
Source: International Journal of Rheumatology

Myocardial involvement is an important prognostic factor in patients with systemic sclerosis, and early diagnosis and staging of the disease have been sought after. Since myocardial damage is characterized by connective tissue disease, including fibrosis and diffuse vascular lesions or microcirculation, nuclear myocardial perfusion imaging has been a promising option for evaluating myocardial damages in early stages.

in this section...

SRF Mailing List

donate now

Make an online contribution
to help find a cure for
scleroderma. It’s fast, secure and simple.

quick links

moving forward video

"Moving Forward" is a five minute video sharing the struggles presented by scleroderma.

Ways to Give

There are many ways that you can support the work of the Scleroderma Research Foundation. We are grateful for your commitment to helping the SRF fund research that will result in improved therapies and, ultimately, a cure.

» Click here for details

Make a Donation 1-800-441-CURE (2873)

The Scleroderma Research Foundation is a 501(c)3 nonprofit organization whose mission is to fund and facilitate the most promising medical research aimed at improved therapies and, ultimately, a cure for scleroderma. Information provided by the SRF should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The SRF does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Scleroderma varies substantially from one patient to another, and treatment must be tailored by a physician for each individual case.